Breast Cancer
|
Stage I - III
ER+ HER2-
|
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Link to ClinicalTrial.gov
|
Dr Valerie Heong
|
Breast Cancer
|
HER2+
PIK3CA MT (Centrally tested)
|
INAVO122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Link to ClinicalTrial.gov
|
Dr Chia Yee Hong
|
Breast Cancer
|
ER+ HER2-
|
ELEVATE
A Phase II randomized trial of Lenvatinib combined with Letrozole versus Fulvestrant in Metastatic Estrogen Receptor (ER) positive, HER2 negative breast cancer, who have progressed on first-line aromatase inhibitor + a CDK4/6 inhibitor.
Link to ClinicalTrial.gov
|
Dr Lavina Bharwani
|
Lung Cancer
|
Stage IB - IIIA NSCLC
RET fusion+ (Centrally tested)
|
LIBRETTO-432
A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC
Link to ClinicalTrial.gov
|
Dr Chia Puey Ling
|
Lung Cancer
|
Unresectable Stage III NSCLC
ALK fusion+
(ROS & RET cohorts closed)
|
BX43361/BO42777
A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Lung Cancer
|
NSCLC
(Non-Sq)
EGFR ex20ins |
REZILIENT-3
Randomized, Controlled, Open-label, Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Lung Cancer
|
NSCLC
(Non-Sq)
HER2 Overexpression (Centrally tested)
|
DESTINY-Lung03
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE)
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Lung Cancer
|
NSCLC
(Non-Sq)
KRAS p.G12C
PD-L1 Negative (TPS<1%)
|
CodeBreaK 202
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Lung Cancer
|
NSCLC (Non-sq)
HER2 activating mutation
|
SOHO-02
A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
with HER2-activating mutations.
Link to ClinicalTrial.gov
|
Dr Ang Kay Hooi John
|
Lung Cancer
|
NSCLC (Non-sq/Sq)
No actionable mutations in 1L setting
PD-L1 High (TPS>50%)
|
GALAXIES LUNG-301
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Lung Cancer
|
NSCLC
(Non-Sq)
EGFR Ex19del or L858R
MET Overexpression / Amplification (Centrally tested)
|
SAFFRON
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
Link to ClinicalTrial.gov
|
Dr Chia Puey Ling
|
Lung Cancer
|
NSCLC (Sq)
|
HMBD-001
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Upper GI Tract Cancer
|
Gastric or GEJ Adenocarcinoma
HER2-
Claudin18.2 IHC positive (Centrally tested)
|
CLARITY
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Pancreatic Cancer
|
Pancreatic ductal adenocarcinoma
Claudin18.2 IHC positive (Centrally tested)
|
CLARITY
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2.
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Head and Neck Cancer / NPC
|
NPC
Stage III-IVA
High Risk
(EBV DNA >/= 4000 copies/ml OR
N2-3 or T4N+)
|
RIBBON-LA-01
Single-arm, open-label, phase 2 trial of tislelizumab and metronomic capecitabine as maintenance therapy in high-risk locoregionally advanced nasopharyngeal carcinoma
Link to ClinicalTrial.gov
|
Dr Jens Samol
|
Genitourinary Cancer (Prostate Cancer)
|
Metastatic, castrate resistant
|
MK-5684-003
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Link to ClinicalTrial.gov
|
Dr Elise Vong
|
Genitourinary Cancer (Prostate Cancer)
|
Metastatic, castrate resistant
|
MK-5684-004
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)
Link to ClinicalTrial.gov
|
Dr Elise Vong
|
Haematology (non-malignancy)
|
Primary Immune Thrombocytopenia
|
CVAY736I2301
A phase III, randomized, double-blind study of ianalumab (VAY736)
versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAYHIT1)
Link to ClinicalTrial.gov
|
Dr Vanessa Chong
|
Haematology (non-malignancy)
|
wAIHA
|
CVAY736O12301
A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)
Link to ClinicalTrial.gov
|
Fong Sing Zern
|